文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

心脏骤停后早期呼吸机相关性肺炎的预防

Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest.
PubMed 文献 · N Engl J Med · 2019-01-01
一句话结论院外心脏骤停可除颤心律患者目标温度管理32–34°C期间,2天阿莫西林-克拉维酸预防性治疗降低早期VAP发生率(19% vs 34%,HR 0.53)。

这项多中心、双盲、随机、安慰剂对照试验纳入198例院外心脏骤停(初始可除颤心律)后接受32–34°C目标温度管理的机械通气成人ICU患者,排除正在抗生素治疗、多重耐药菌慢性定植或濒死状态者。干预为心脏骤停后6小时内开始静脉阿莫西林-克拉维酸(分别为1 g和200 mg)每日三次共2天,对照为安慰剂。主要终点早期VAP(住院前7天)发生率抗生素组19% vs 安慰剂组34%(HR 0.53,95%CI 0.31–0.92,P=0.03)。晚期VAP、无呼吸机天数、ICU住院时间及28天死亡率组间无显著差异,第7天耐药菌未增加,严重不良事件无显著差异。

要点

  • 院外心脏骤停初始可除颤心律、32–34°C目标温度管理机械通气成人,早期VAP发生率阿莫西林-克拉维酸组19% vs 安慰剂组34%(HR 0.53,95%CI 0.31–0.92,P=0.03)。
  • 干预为心脏骤停后<6小时开始静脉阿莫西林-克拉维酸(1 g/200 mg)每日三次共2天。
  • 晚期VAP(4% vs 5%)、无呼吸机天数(21天 vs 19天)、28天死亡率(41% vs 37%)组间无显著差异。
  • 第7天耐药菌未增加,严重不良事件两组无显著差异。
  • 排除正在抗生素治疗、多重耐药菌慢性定植或濒死状态患者。

适用人群与场景

  • 成人(>18岁)ICU患者,院外心脏骤停且初始为可除颤心律,接受机械通气及32–34°C目标温度管理。
  • 排除:正在抗生素治疗、多重耐药菌慢性定植或濒死状态患者。

处置流程与药物剂量

  • 心脏骤停后<6小时开始静脉阿莫西林-克拉维酸(剂量分别为1 g和200 mg),每日三次,共2天。

研究设计与关键结果

  • 多中心、双盲、随机、安慰剂对照试验,198例随机,194例纳入分析。
  • 早期VAP(住院前7天)经独立裁定委员会确认:抗生素组19例(19%)vs 安慰剂组32例(34%),HR 0.53(95%CI 0.31–0.92),P=0.03。
  • 晚期VAP发生率抗生素组4% vs 对照组5%,无显著差异。
  • 无呼吸机天数抗生素组21天 vs 对照组19天,无显著差异。
  • ICU住院时间:出院患者抗生素组5天 vs 对照组8天;死亡患者两组均为7天 vs 7天,无显著差异。
  • 28天死亡率抗生素组41% vs 对照组37%,无显著差异。
  • 第7天耐药菌未增加,严重不良事件两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于院外心脏骤停初始可除颤心律、接受32–34°C目标温度管理的机械通气成人,可于心脏骤停后<6小时开始2天静脉阿莫西林-克拉维酸(1 g/200 mg,每日三次)以降低早期VAP发生率。
  • 该策略未显著改善无呼吸机天数、ICU住院时间或28天死亡率,临床决策需权衡早期VAP预防与上述结局。
  • 不适用于正在抗生素治疗、多重耐药菌慢性定植或濒死状态患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients who are treated with targeted temperature management after out-of-hospital cardiac arrest with shockable rhythm are at increased risk for ventilator-associated pneumonia. The benefit of preventive short-term antibiotic therapy has not been shown.

METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving adult patients (>18 years of age) in intensive care units (ICUs) who were being mechanically ventilated after out-of-hospital cardiac arrest related to initial shockable rhythm and treated with targeted temperature management at 32 to 34°C. Patients with ongoing antibiotic therapy, chronic colonization with multidrug-resistant bacteria, or moribund status were excluded. Either intravenous amoxicillin-clavulanate (at doses of 1 g and 200 mg, respectively) or placebo was administered three times a day for 2 days, starting less than 6 hours after the cardiac arrest. The primary outcome was early ventilator-associated pneumonia (during the first 7 days of hospitalization). An independent adjudication committee determined diagnoses of ventilator-associated pneumonia.

RESULTS: A total of 198 patients underwent randomization, and 194 were included in the analysis. After adjudication, 60 cases of ventilator-associated pneumonia were confirmed, including 51 of early ventilator-associated pneumonia. The incidence of early ventilator-associated pneumonia was lower with antibiotic prophylaxis than with placebo (19 patients [19%] vs. 32 [34%]; hazard ratio, 0.53; 95% confidence interval, 0.31 to 0.92; P = 0.03). No significant differences between the antibiotic group and the control group were observed with respect to the incidence of late ventilator-associated pneumonia (4% and 5%, respectively), the number of ventilator-free days (21 days and 19 days), ICU length of stay (5 days and 8 days if patients were discharged and 7 days and 7 days if patients had died), and mortality at day 28 (41% and 37%). At day 7, no increase in resistant bacteria was identified. Serious adverse events did not differ significantly between the two groups.

CONCLUSIONS: A 2-day course of antibiotic therapy with amoxicillin-clavulanate in patients receiving a 32-to-34°C targeted temperature management strategy after out-of-hospital cardiac arrest with initial shockable rhythm resulted in a lower incidence of early ventilator-associated pneumonia than placebo. No significant between-group differences were observed for other key clinical variables, such as ventilator-free days and mortality at day 28. (Funded by the French Ministry of Health; ANTHARTIC ClinicalTrials.gov number, NCT02186951.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. François B, Cariou A, Clere-Jehl R, et al. Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest. N Engl J Med. 2019. PMID: 31693806. doi:10.1056/NEJMoa1812379

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。